Physician profile
Robert A Rovner
NPI 1871560482
$101,571.26
in general payments reported to CMS, 2019-2025
10 companies · $3,800 in 2025
The $3,800 reported for 2025 was more than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,759 · 2020: $25K · 2021: $8,550 · 2022: $29K · 2023: $12K · 2024: $15K · 2025: $3,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,982.00 |
| Food and Beverage | $679.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovasis INC | $66,151.36 | 2020-2025 | |
| Precision Spine, INC. | $32,459.19 | 2019-2025 | |
| Globus Medical, INC. | $2,295.69 | 2019-2020 | |
| Terumo Bct, INC. | $187.32 | 2019 | |
| Centinel Spine, LLC | $164.72 | 2025 | Prodisc C Vivo |
| Heron Therapeutics, INC. | $127.49 | 2025 | Zynrelef |
| Gs Solutions, INC. | $124.83 | 2023 | |
| Ascendis Pharma Endocrinology INC | $29.40 | 2025 | Yorvipath |
| Depuy Synthes Sales INC. | $16.89 | 2020 | |
| Si-Bone, INC. | $14.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rovner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.